Brexpiprazole
FDA-approved product (tablet, oral), marketed as Brexpiprazole, Rexulti.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Major depressive disorder
- Psychosis
- Schizoaffective disorder
- Schizophrenia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antipsychotics
- FDA pharmacologic class
- Atypical Antipsychotic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Brexpiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
NCT01837797 · start 2013-04
Registered record
- Registry ID
- NCT01837797
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo; Brexpiprazole 1 mg; Brexpiprazole 3 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2013-04
- Completion
- 2014-05
- Enrolment
- 129
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Depressive DisorderInterventionPlacebo; Brexpiprazole 1 mg; Brexpiprazole 3 mgPhasePhase 3Registry statusTerminatedBrexpiprazole in Patients With Acute Schizophrenia
NCT01810380 · start 2013-03
Registered record
- Registry ID
- NCT01810380
- Conditions
- Schizophrenia
- Interventions
- Placebo; Brexpiprazole; Quetiapine extended release
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-03
- Completion
- 2014-12
- Enrolment
- 468
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionPlacebo; Brexpiprazole; Quetiapine extended releasePhasePhase 3Registry statusCompletedEfficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
NCT01668797 · start 2012-10
Registered record
- Registry ID
- NCT01668797
- Conditions
- Acute Schizophrenia
- Interventions
- Brexpiprazole; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2015-02
- Enrolment
- 524
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute SchizophreniaInterventionBrexpiprazole; PlaceboPhasePhase 3Registry statusCompletedPhase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
NCT01670279 · start 2012-07
Registered record
- Registry ID
- NCT01670279
- Conditions
- Major Depressive Disorder
- Interventions
- Brexpiprazole; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-07
- Completion
- 2013-05
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Depressive DisorderInterventionBrexpiprazole; PlaceboPhasePhase 1Registry statusCompletedSafety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
NCT01360866 · start 2011-10
Registered record
- Registry ID
- NCT01360866
- Conditions
- Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders
- Interventions
- OPC-34712; Escitalopram; Fluoxetine; Paroxetine CR; Sertraline; Duloxetine; Venlafaxine XR
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-10
- Completion
- 2017-05-18
- Enrolment
- 2,944
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDepressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders +1 moreInterventionOPC-34712; Escitalopram; Fluoxetine; Paroxetine CR +3 morePhasePhase 3Registry statusCompleted